Wieslab® Complement System Screen kits (Wieslab AB, Malmö, Sweden) were used to measure complement activation via the CP, the LP (MBL-dependent), and the AP in the serum of participants according to the manufacturer’s instructions. All determinations were performed in duplicate.
Serum and EDTA-plasma concentrations of complement activation products were measured using ELISA kits according to the manufacturers' instructions, with sample dilutions adjusted to fall within the linear range of standard curves. MicroVue™ EIA kits from Quidel Corporation (San Diego, USA) were used to measure C5a (cat #A025), sC5b-9 (cat #A029), Ba (cat #A033), Bb (cat #A027), and C4d (cat #A009). Hycult Biotech kits (Uden, NE) were used to measure FD (cat #HK343) and FH (cat #HK342). Serum levels of IL-6 were measured using the Simoa HD-1 platform (Quanterix Corporation, Billerica, USA), as previously reported [25 (link)]. Reported precision for each complement ELISA kit are listed as follows (analyte, coefficient of variation): C5a, ≤ 3.9%; sC5b-9, ≤ 6.8%; Ba, 2.3%; Bb, ≤ 4%; C4d, ≤ 9.7%. Precision characteristics were not available for FD and FH kits. All samples were tested in duplicate and only values with a CV of ≤ 15% were included in analyses.